Welcome to our dedicated page for Brainsway Ltd. SEC filings (Ticker: BWAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the revenue split between Deep TMS device sales and leases or tracking when a director exercises options inside a 200-page filing can feel overwhelming. BrainsWay insider trading Form 4 transactions are scattered across multiple exhibits, while risk disclosures span both U.S. and Israeli regulations. If you have ever typed “BrainsWay SEC filings explained simply” into a search bar, you already know how scarce clear answers are.
Stock Titan ends that search. Our AI-powered summaries turn the latest BrainsWay quarterly earnings report 10-Q filing into an easy-to-scan brief in seconds. The platform streams BrainsWay Form 4 insider transactions real-time, flags option grants, and links them to market-moving announcements. Whether you are understanding BrainsWay SEC documents with AI for a diligence memo or need quick BrainsWay earnings report filing analysis, key figures—installed system count, recurring treatment revenue, R&D spend—stand out instantly.
Every document type is covered: the BrainsWay annual report 10-K simplified highlights reimbursement risk and FDA-cleared indications; the BrainsWay 8-K material events explained alerts you to fresh clinical data or new approvals; and the BrainsWay proxy statement executive compensation reveals how patient-treatment milestones drive leadership bonuses. Investors use these insights to:
- Compare segment margins across device sales and leasing
- Monitor BrainsWay executive stock transactions Form 4 before major data releases
- Track adoption trends quarter over quarter
With real-time EDGAR updates, comprehensive coverage of all forms, and expert notes beside each section, Stock Titan turns dense disclosures into actionable knowledge.
Alpha Teknova, Inc. (TKNO) – Form 4 insider transaction
Director Martha J. Demski reported a single open-market sale of the company’s common stock on 27 June 2025. The transaction was executed under a Rule 10b5-1 trading plan adopted 12 March 2025 and was expressly intended to cover tax obligations arising from the vesting of director restricted stock units.
- Securities sold: 8,000 common shares
- Sale price: $5.064 per share
- Gross proceeds: approximately $40,512
- Post-transaction ownership: 12,000 common shares held directly
No derivative securities were acquired or disposed of, and no other transactions were reported. After the sale, Demski retains a direct equity interest in the company, but her share count declined by 40% from 20,000 to 12,000 shares. Because the disposition was pre-programmed under a 10b5-1 plan and earmarked for tax withholding, it is generally viewed as administrative rather than indicative of a changed outlook. Nevertheless, investors often monitor insider sales—especially by board members—for potential signaling effects. The filing does not disclose any changes to Demski’s role, company strategy, or financial performance.
FAQ
What is the current stock price of Brainsway Ltd. (BWAY)?
What is the market cap of Brainsway Ltd. (BWAY)?
What is the core technology behind BrainsWay Ltd?
How does BrainsWay generate its revenue?
Which mental health conditions does BrainsWay target with its technology?
What makes Deep TMS different from other brain stimulation therapies?
How is BrainsWay positioned within the neurostimulation market?
What evidence supports the efficacy of BrainsWay's technology?
